Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Avita Medical, Inc. - Common Stock (NQ:RCEL)

16.59 +0.91 (+5.80%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Avita Medical, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
AVITA Medical (RCEL) Q3 2026 Earnings Call Transcript ↗
Going concern warning removed as revenue jumps and guidance rises again. 
Via The Motley Fool
Topics Earnings
News headline image
Avita Medical Q3 Earnings Call Highlights ↗
Avita Medical (NASDAQ:RCEL) raised its full-year revenue forecast for the second consecutive quarter after third-quarter sales rose 53% from a year earlier, driven by demand for its RECELL wound... 
Via MarketBeat
Topics Earnings
AVITA Medical (NASDAQ:RCEL) Posts Q3 Beat and Raises 2026 Revenue Guidance ↗
Via Chartmill
After-Hours Market Movers for Nov. 5, 2026: Gainers and Losers ↗
Via Chartmill
Avita Medical (NASDAQ:RCEL) Beats Q2 Estimates and Raises Full-Year Guidance ↗
Via Chartmill
AVITA Medical (NASDAQ:RCEL) Q1 2026 Revenue Beat Fails to Offset Wider Loss, Stock Still Rises on Outlook ↗
Via Chartmill
News headline image
AVITA Medical Reports Third Quarter Results
From AVITA Medical
Via GlobeNewswire
News headline image
AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027
From AVITA Medical
Via GlobeNewswire
News headline image
AVITA Medical to Announce Third Quarter 2026 Financial Results
From AVITA Medical
Via GlobeNewswire
News headline image
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
From AVITA Medical
Via GlobeNewswire
News headline image
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft ↗
Avita Medical (NASDAQ:RCEL) presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness... 
Via MarketBeat
News headline image
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
From AVITA Medical
Via GlobeNewswire
News headline image
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18% ↗
Avita Medical (NASDAQ:RCEL) reported second-quarter 2026 revenue of $21.7 million, up 13% sequentially from $19.3 million in the first quarter and 18% from $18.4 million a year earlier, as the... 
Via MarketBeat
News headline image
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds ↗
Avita Medical (NASDAQ:RCEL) expects continued sequential revenue growth and aims to reach cash flow breakeven in the fourth quarter of 2025, President and CEO Cary Vance said at the Canaccord 46th... 
Via MarketBeat
News headline image
AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript ↗
Revenue exceeded $21.7 million with guidance raised to $86M–$89M for full year. 
Via The Motley Fool
Topics Earnings
News headline image
AVITA Medical to Host Investor Webinar Briefing
From AVITA Medical
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out... 
Via Benzinga
What's going on in today's session ↗
Via Chartmill
Which stocks are gapping on Friday? ↗
Via Chartmill
News headline image
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
From AVITA Medical
Via GlobeNewswire
News headline image
Avita Medical Q2 Earnings Call Highlights ↗
Avita Medical (NASDAQ:RCEL) reported second-quarter 2026 revenue of $21.7 million, up 18% from a year earlier and 13% sequentially, as growth in its RECELL wound-care product and newer portfolio... 
Via MarketBeat
Topics Earnings
News headline image
AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
From AVITA Medical
Via GlobeNewswire
News headline image
AVITA Medical to Announce Second Quarter 2026 Financial Results
From AVITA Medical
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million. Lisata Therapeutics... 
Via Benzinga
News headline image
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
From AVITA Medical
Via GlobeNewswire
News headline image
AVITA Medical to Host Investor Webinar Briefing
From AVITA Medical
Via GlobeNewswire
News headline image
Avita (RCEL) Q1 2026 Earnings Call Transcript ↗
Avita (RCEL) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Avita Medical Q1 Earnings Call Highlights ↗
Avita Medical (NASDAQ:RCEL) reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook as management said reimbursement conditions for its RECELL product are normalizing and demand... 
Via MarketBeat
Topics Earnings
News headline image
AVITA Medical Reports First Quarter 2026 Financial Results
From AVITA Medical
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.